Hostname: page-component-7b7567c8c-slfcl Total loading time: 0 Render date: 2026-11-19T15:46:35.687Z Has data issue: false hasContentIssue false

Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review

Published online by Cambridge University Press:  16 April 2020

Panayotis P. Ferentinos
Affiliation:
Department of Psychiatry, Eginition Hospital, University of Athens, 74 Vas. Sophias Avenue, 11528Athens, Greece
Beata J. Havaki-Kontaxaki
Affiliation:
Department of Psychiatry, Eginition Hospital, University of Athens, 74 Vas. Sophias Avenue, 11528Athens, Greece
Dimitris K. Roukas
Affiliation:
Department of Psychiatry, Eginition Hospital, University of Athens, 74 Vas. Sophias Avenue, 11528Athens, Greece
Get access

Abstract

Approximately 40–70% of treatment-resistant schizophrenic patients fail to benefit from clozapine monotherapy or are partial responders. During the last years several clozapine adjunctive agents have come into clinical practice. This study aims to critically review all published randomized, double-blind, placebo-controlled clinical trials (RCTs) regarding the efficacy and safety of adjunctive agents in clozapine-resistant schizophrenic or schizoaffective patients. A MEDLINE search for RCTs on clozapine adjunctive agents published from January 1980 to February 2004 was conducted. All identified papers were critically reviewed and examined against several methodological features as well as clinical and pharmacological parameters. Eleven trials including 270 patients, partial or non-responders to clozapine, assessed the efficacy of sulpiride, lithium, lamotrigine, fluoxetine, glycine, d-serine, d-cycloserine and ethyl-eicosapentanoate (E-EPA) as clozapine adjuncts. There were eight parallel-group and three crossover trials. The inclusion criteria varied widely. The duration as well as the dosage of clozapine monotherapy were reported adequate in only one trial. Plasma clozapine levels were assessed in only three trials. Main side-effects reported were hypersalivation, sedation, diarrhea, nausea, hyperprolactinaemia. The outcome favored clozapine augmentation with sulpiride, lamotrigine and E-EPA. Lithium was shown to benefit only schizoaffective patients. However, the methodological shortcomings of trials analyzed limit the impact of evidence provided.

Information

Type
Review
Copyright
Copyright ©Elsevier SAS 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Submit a response

Comments

No Comments have been published for this article.